Clinical Trial Update: PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of a PD-1 inhibitor, Bevacizumab, and a PCSK-9 inhibitor in advanced non-small cell lung cancer patients who pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PCSK-9 inhibitor (unspecified)
• PD-1 inhibitor (unspecified)

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Resistance to Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING